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ABSTRACT
Between January 2001 and December 2005, 1263
patients suspected of having echinococcosis were
screened serologically by indirect haemagglutina-
tion assay (IHA). IHA-positive patient sera were
then retested by western blot for confirmation and
differentiation between Echinococcus granulosus
and Echinococcus multilocularis infection. Of 43
sera confirmed as Echinococcus-positive, nine
appeared to be specific for alveolar echinococcosis
(AE) caused by E. multilocularis. AE-positive se-
rological results corresponded to the clinical
and ⁄ or imaging findings concerning the patients’
liver cysts. The detected incidence of AE was
0.45 ⁄ 105 inhabitants, which suggests that clini-
cians and health authorities in Slovenia should
give greater attention to AE in the future.
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Human echinococcosis is caused mainly by the
larvae of the tapeworm Echinococcus granulosus,
which cause cystic echinococcosis (CE), and by
the larvae of Echinococcus multilocularis, which can
cause alveolar echinococcosis (AE). E. granulosus
occurs worldwide, but E. multilocularis is found
only in the temperate northern hemisphere. The
main endemic areas of this tapeworm are Alaska,
Canada, central North America, some parts of
central western Europe, western Turkey, Russia,
China, central Asia and northern Japan. At the
adult stage, E. multilocularis is 1.2–3.7 mm in
length and is harboured in the intestine of
definitive hosts, typically foxes, and also domestic
dogs and cats. The tapeworm eggs are excreted
with the faeces. Following accidental ingestion of
these eggs, the larval stage of AE may develop in
many species of small rodents, and sometimes in
humans as intermediate hosts, usually in the liver.
AE is potentially fatal and is chronically progres-
sive as a tumour-like hepatic disease [1–6]. The
aim of the present study was to examine ser-
ologically whether patients in Slovenia suspected
of having echinococcosis had been infected by the
larvae of E. multilocularis.
Between 1 January 2001 and 31 December 2005,
1263 patients suspected of having echinococcosis
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(because of lesions in the liver and ⁄ or lung,
and ⁄ or findings from ultrasound scanning or
computerised tomography, e.g., different forms,
size and number of lesions) were examined
serologically. Sera were obtained from patients
of both genders and different ages, and from
varying areas of Slovenia. The sera were screened
by an indirect haemagglutination assay (IHA)
(Cellognost-Echinococcosis; Dade Behring,
Marburg, Germany).
Low positive IHA titres of 1:32–1:128 should
only be accepted as positive for echinococcosis
when they are confirmed in conjunction with a
second serological method (e.g., immunofluores-
cence test, ELISA or western blot (WB)). For
confirmation and differentiation between CE and
AE, all IHA-positive sera were retested by WB
IgG (LDBIO Diagnostics, Lyon, France). Accord-
ing to the manufacturer’s interpretation data and
the evaluation of Liance et al. [7], immunoblot
patterns P1, with only a 7-kDa band, and P2,
with a band at 7 kDa and at least a diffuse band
at 16–18 kDa, are specific for CE. Pattern P3,
with at least one band at 26–28 kDa plus two
sharp bands at 16 and 18 kDa, is the most
specific pattern for AE. Pattern P4, with one
26–28 kDa band only, is also c. 88% specific for
AE. Pattern P5, with a band at 7 kDa and a band
at 26–28 kDa only, cannot be used to discrimin-
ate between the two species [7]. Because of
possible cross-reactivity with neurocysticercosis,
E. multilocularis-positive sera were retested using
an immunoblot assay (Cysticercosis WB IgG;
LDBIO Diagnostics).
In 93 of 1263 sera from patients with suspected
echinococcosis, antibodies to Echinococcus spp.
with low-to-high titres were detected by IHA. Of
93 IHA-positive sera, 43 were also positive for
echinococcosis by WB. Of these 43 sera, 20 sera
with patterns P1 or P2, and 14 sera with pattern
P5 were not studied further. Nine of 43 sera
appeared to be positive for AE caused by
E. multilocularis, as the antibodies in these sera
bound specifically to antigens of 26–28 kDa.
Seven of these nine sera (four with IHA titres
of 1:32–1:128, one with a titre of 1:256, one with a
titre of 1:512, and one with a titre of 1:1024) were
from women, aged 60, 31, 57, 46, 68, 79 and
62 years, respectively, while two sera (IHA titres
1:32 and 1:64) were from men, aged 66 and
65 years, respectively. The serological results
corresponded with the clinical data (jaundice,
epigastric pain, hepatomegaly, anaemia) and ⁄ or
the imaging findings (single irregular and ⁄ or
small multiple, and some calcified lesions in the
patients’ livers). All AE-positive sera were neg-
ative for cysticercosis according to the immuno-
blot assay.
AE develops almost exclusively in the liver
(99% of cases), with a fatality rate of >90% in
untreated patients. The typical transmission cycle
in Europe involves red foxes as final hosts, and
small rodents (different species of voles and mice)
as intermediate hosts. In many cities, towns and
villages in southern central Europe, foxes have
adapted to urban environments and bring the
parasite to human settlements. This urban cycle of
the parasite in red foxes and their intermediate
hosts is likely to lead to an increased risk of
infection from domestic dogs and possibly cats
[8–10].
In the 1980s, human AE occurred in Europe
only in Austria, France, Germany and Switzer-
land, but since the 1990s, sporadic cases have
also been reported in Belgium, Poland, the Czech
Republic, Slovakia and Greece [2,3,8,11,12]. AE
usually manifests in older patients because of
its characteristic asymptomatic incubation period
of 5–15 years. The mean age of AE patients in the
present study was 59.3 years, which is in agree-
ment with findings published previously [8,12].
The incidence of AE in Slovenia in 2001–2005 has
been estimated as 0.45 ⁄ 105 inhabitants, with a
mean annual incidence of 0.09 cases ⁄ 105 inhabit-
ants. The patients in the present study were from
southern and north-eastern parts of Slovenia.
This region is agricultural and is populated by
small rodents that are the primary intermediate
hosts for transmission of the parasite. Based on a
report of AE in Slovenian cattle in 1966 [13] and
a report of AE in the Apodemus flavicollis mouse
in 1984 [14], it seems that human AE may also
have been present previously in Slovenia, but
remained undetected or overlooked because of
insufficient investigations and serological tests
unsuitable for accurate confirmation and differ-
entiation between CE and AE. It is also possible
that AE might have been transmitted from the
southern region of Austria, bordering Slovenia,
where E. multilocularis was reported in foxes
during the 1980s [8].
It is difficult to understand the precise ecol-
ogy of the parasite and the route of infection of
humans. None of the AE-positive patients in the
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present study was a farmer or hunter, but most
owned, or formerly kept, dogs or cats, and these
could be a possible risk-factor for this infection
[15,16]. Overall, the results of this study suggest
that clinicians and health authorities in Slo-
venia should give greater attention to AE in the
future.
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ABSTRACT
Paediatric patients hospitalised with varicella
(n = 1575) were reported to a French national
network between March 2003 and July 2005.
Superinfection was identified in 50.3% of cases,
principally of skin and soft-tissue (36.5%). The risk
of superinfection increased with fever relapse, use
of non-steroidal anti-inflammatory drugs, pro-
longed fever, an age of 1–5 years, and contamina-
tion at the childminder’s home. Neurological com-
plications were observed in 7.8% of cases, while
pulmonary complications were less frequent
(3.1%). Forty-nine patients had sequelae and eight
patients died. Surveillance should continue in
France with a view to the future implementation
of a universal vaccination programme.
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Varicella is a mild infectious disease preventable by
vaccination [1,2]. Only high-risk individuals are
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